Human-derived normal mesenchymal stem/stromal cells in anticancer therapies

J Cancer. 2017 Jan 1;8(1):85-96. doi: 10.7150/jca.16792. eCollection 2017.

Abstract

The tumor microenvironment (TME) not only plays a pivotal role during cancer progression and metastasis, but also has profound effects on therapeutic efficacy. Stromal cells of the TME are increasingly becoming a key consideration in the development of active anticancer therapeutics. However, dispute concerning the role of stromal cells to fight cancer continues because the use of mesenchymal stem/stromal cells (MSCs) as an anticancer agent is dependent on the specific MSCs subtype, in vitro or in vivo conditions, factors secreted by MSCs, types of cancer cell lines and interactions between MSCs, cancer cells and host immune cells. In this review, we mainly focus on the role of human-derived normal MSCs in anticancer therapies. We first discuss the use of different MSCs in the therapies for various cancers. We then focus on their anticancer mechanism and clinical application.

Keywords: Cancer; Mesenchymal stem/stromal cells; Tumor microenvironment..

Publication types

  • Review